Pumarix

Pumarix (and its variants such as Adjupanrix) is an AS03-adjuvanted, monovalent, inactivated, split-virion influenza vaccine developed by GSK to provide protection against the H5N1 subtype of avian influenza. The vaccine is designed for use in pre-pandemic or pandemic scenarios. It contains purified hemagglutinin (HA) and neuraminidase (NA) antigens from specific H5N1 strains, such as A/Indonesia/5/05 or A/VietNam/1194/2004. The vaccine is formulated with the proprietary AS03 adjuvant system, an oil-in-water emulsion containing squalene, alpha-tocopherol, and polysorbate 80, which enhances the magnitude and breadth of the immune response while allowing for antigen dose-sparing. The provided name 'teriparatide-GlaxoSmithKline-avian influenza (H5N1)' is factually incorrect as it incorrectly prepends the name of an unrelated osteoporosis drug (teriparatide) to the GSK H5N1 vaccine description.

Brand names

PumarixAdjupanrixPrepandrix

Other names

AS03-adjuvanted H5N1 vaccineAS-03-adjuvanted H5N1 vaccineAS 03-adjuvanted H5N1 vaccineInfluenza A (H5N1) Virus Monovalent VaccineMonovalent A/Indonesia/5/05 (H5N1) Vaccine Antigen